Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366943 | 0.81 | GPBAR1 (0.44) | NR1H3NR1H2GPBAR1POLQHDAC6 | |
| SCHEMBL27855990 | 0.78 | KMT2A (0.41) | NR1H3NR1H2HDAC6KDM4EKMT2A | |
| SCHEMBL9001643 | 0.76 | KMT2A (0.53) | NR1H3NR1H2KDM4EKMT2A | |
| SCHEMBL10878726 | 0.75 | KDM4E (0.46) | NR1H3NR1H2GPBAR1KDM4EKMT2A | |
| SCHEMBL10672986 | 0.74 | POLB (0.44) | NR1H3NR1H2POLQHDAC8HDAC6 | |
| SCHEMBL16439866 | 0.73 | SMN1; SMN2 (0.51) | HDAC8 | |
| SCHEMBL7754437 | 0.72 | POLB (0.39) | NR1H3NR1H2POLQHDAC6KMT2A | |
| SCHEMBL943132 | 0.72 | KDM4E (0.46) | NR1H3NR1H2HDAC8KDM4EKMT2A | |
| SCHEMBL2088432 | 0.72 | POLQ (0.50) | GPBAR1POLQHDAC6KDM4E | |
| SCHEMBL4981268 | 0.71 | GPBAR1 (0.44) | GPBAR1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | NR1H3 813/4885NR1H2 563/4885GPBAR1 1271/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | NR1H3 591/4885NR1H2 441/4885GPBAR1 1562/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | NR1H3 760/4885NR1H2 519/4885GPBAR1 1262/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | NR1H3 806/4885NR1H2 554/4885GPBAR1 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.